So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, hormone-sensitive, latitude, metastatic, mHSPC, nmHSPC, non-metastatic, STAMPEDE | 1 Comment »
One of the clinical questions that is now beginning to be asked really seriously is this one: “Just how aggressively should we treat a man with high-risk progressive prostate cancer after first-line therapy?” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", abiraterone, androgen, annihilation, apalutimide, Degarelix, hormone-sensitive, nmHSPC, non-metatstaic | 8 Comments »
If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.
Our most recent CureTalk on Prostate Cancer (on February 21 this year) features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.
For access to the full list of CureTalks on Prostate Cancer, please click here.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
